Viatris Reports Strong Q1 Adjusted EPS Beat and Reaffirms Full-Year 2026 Financial Guidance
Summary
Viatris Inc. announced strong first-quarter 2026 financial results, beating adjusted EPS estimates and reaffirming its full-year guidance, driven by operational growth and new product revenues.
Key Events
-
Q1 Adjusted EPS Beat
Viatris reported adjusted EPS of $0.59 for Q1 2026, surpassing the IBES estimate of $0.50, representing an 18% reported increase and 14% operational increase compared to Q1 2025.
-
Strong Revenue and EBITDA Growth
Total revenues reached $3.5 billion, up 8% on a reported basis and 3% operationally from Q1 2025. Adjusted EBITDA grew 14% reported and 10% operationally to $1.0 billion, demonstrating solid operating leverage.
-
2026 Financial Guidance Reaffirmed
The company reaffirmed its full-year 2026 financial guidance ranges for Total Revenues, Adjusted EBITDA, Adjusted EPS, and Free Cash Flow, indicating confidence in its outlook.
-
Pipeline Progress and New Product Revenues
Viatris highlighted progress in key launches and pipeline milestones, including the launch of Effexor® for Generalized Anxiety Disorder in Japan, and generated approximately $71 million in new product revenues for the quarter.
Analysis
Viatris Inc. delivered a strong first quarter, exceeding analyst expectations for adjusted EPS and demonstrating solid operational growth in revenues and Adjusted EBITDA. The reaffirmation of full-year 2026 financial guidance provides stability and confidence, especially following the recent announcement of its CFO's departure. This positive financial performance, coupled with progress in key product launches and pipeline milestones, could support investor sentiment as the stock trades near its 52-week high.
At the time of this filing, VTRS was trading at $15.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6B. The 52-week trading range was $8.19 to $16.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.